What is the recommended management for a patient with dilated cardiomyopathy and serum ferritin >3000 µg/L, and for a relative with dilated cardiomyopathy who is on dialysis?

Management of Dilated Cardiomyopathy with Ferritin >3000 µg/L

You must urgently investigate for hemochromatosis (hereditary or secondary iron overload) as the underlying cause of dilated cardiomyopathy when ferritin exceeds 3000 µg/L, and initiate aggressive iron reduction therapy with therapeutic phlebotomy or iron chelation, as untreated cardiac hemochromatosis carries a survival of less than one year but can be reversed with early treatment 1.

Immediate Diagnostic Workup for the Index Patient

The extremely elevated ferritin (>3000 µg/L) in the context of dilated cardiomyopathy strongly suggests iron overload cardiomyopathy. You need to:

• Measure transferrin saturation immediately - diagnosis of iron overload requires transferrin saturation >55% along with elevated ferritin >300 ng/mL 1
• Order genetic testing for HFE gene mutations (C282Y and H63D variants) and other iron metabolism proteins (hemojuvelin, transferrin receptor, ferroportin) after excluding secondary causes 1
• Obtain cardiac MRI with T2 relaxation time measurement* - this quantifies myocardial iron burden and guides treatment response. Note that patients can have normal T2 values yet still have subclinical left ventricular dysfunction detectable by strain imaging* 2. The T2* improves significantly after venesection treatment 2
• Perform comprehensive echocardiography with speckle-tracking strain analysis - radial and circumferential strain are superior to T2* measurements for detecting early cardiac involvement and monitoring treatment response 2

Critical Pitfall

Standard echocardiographic ejection fraction may appear normal while myocardial strain is already abnormal 2, 3. Don't rely solely on LVEF - obtain strain imaging.

Treatment Algorithm for Iron Overload Cardiomyopathy

Iron Reduction Therapy (Primary Treatment)

• Therapeutic phlebotomy is first-line for hereditary hemochromatosis
• Iron chelation therapy for secondary hemochromatosis or when phlebotomy is contraindicated
• Monitor response with serial cardiac MRI - T2* values improve with treatment, and radial/circumferential strain normalize as iron is removed 2

Heart Failure Management (Concurrent)

While addressing iron overload, implement standard heart failure therapy per 4:

• ACE inhibitors or ARBs - proven mortality benefit in dilated cardiomyopathy
• Beta-blockers - essential for systolic dysfunction
• Mineralocorticoid receptor antagonists - for advanced heart failure
• SGLT2 inhibitors - newer evidence supports use in dilated cardiomyopathy 5
• Diuretics - for volume management only as needed

Prognosis Context

The average survival is less than one year in untreated patients with severe cardiac impairment from hemochromatosis, but if treated early and aggressively, survival approaches that of the general heart failure population 1. This makes rapid diagnosis and treatment initiation critical.

Management of the Relative on Dialysis with Dilated Cardiomyopathy

For dialysis patients with dilated cardiomyopathy, carvedilol is the preferred beta-blocker as it is the only agent proven in randomized trials to improve left ventricular function, decrease hospitalization, cardiovascular deaths, and total mortality in this specific population 6.

Medication Regimen for Dialysis Patients

First-line therapy:

• Carvedilol (not other beta-blockers) - demonstrated comparable improvement to general population in a randomized trial of dialysis patients with dilated cardiomyopathy 6

Second-line therapy:

• ACE inhibitors - recommended despite limited data in dialysis patients. Dosing must be individualized around each dialysis session to avoid intradialytic hypotension. Expect approximately 30% dropout rate due to hypotension 6

Third-line therapy:

• Digoxin - particularly indicated for ventricular rate control in atrial fibrillation 6

Critical Medications to AVOID in Dialysis Patients

• Diuretics are ineffective and not indicated for volume removal in dialysis patients 6
• Spironolactone/eplerenone should be used with great caution or not at all - causes dangerous hyperkalemia in dialysis patients 6

Volume Management Strategy

• Optimize fluid removal through dialysis prescription rather than diuretics
• Consider quotidian long-duration dialysis for patients who cannot achieve dry weight with conventional thrice-weekly hemodialysis 6
• Use echocardiography with Doppler to assess cardiac filling pressures and volume status non-invasively 6

Family Screening Implications

The presence of dilated cardiomyopathy in both the patient and relative raises two possibilities:

1. Familial hemochromatosis - if the index patient has hereditary hemochromatosis (30-50% of dilated cardiomyopathy cases are familial 4), the relative should undergo genetic testing and iron studies
2. Genetic dilated cardiomyopathy - independent of iron overload, requiring cascade screening of first-degree relatives

Screen all first-degree relatives with echocardiography, genetic testing if a pathogenic variant is identified, and iron studies given the clinical presentation 4.